Epidemiology Trends 2026
The disease curves reshaping pharma demand.
The five epidemiology trends every pharma strategy team should be modeling — aging, NCD acceleration, AMR, climate-linked disease and post-pandemic respiratory patterns.
"Which long-horizon disease curves should reshape our portfolio bets?"
The 2026–2035 disease curve is dominated by aging, NCDs, AMR and climate-linked vector spread. Forecasts that ignore these structural shifts under-call demand by 20–40% for affected TAs.
Long-horizon disease trends are the most under-used input to pharma portfolio strategy. Most teams model a 5-year forecast off current epidemiology and miss the 10–20 year curves that compound disease demand.
Five curves to track
Aging, NCD acceleration, AMR, climate-linked disease and mental-health prevalence are the five durable drivers. Each compounds slowly, but each materially shifts forecast assumptions for at least one major TA.
Translate trends into portfolio decisions
The output of an epi-trends view is not a slide — it is a set of multipliers applied to TA forecasts in the live opportunity model. That is how trends turn into defensible portfolio bets.
What we’re seeing in the data.
Aging compounds NCD demand
Cardio-renal-metabolic, oncology and CNS demand all scale with the over-60 cohort.
AMR is the slow-moving crisis
Antimicrobial resistance materially raises hospital length-of-stay and drives novel-antibiotic policy.
Climate shifts vector disease maps
Dengue, malaria and respiratory disease distributions move with temperature and humidity.
Mental-health prevalence still rising
Post-pandemic mental-health prevalence remains elevated, especially adolescent.
How to think about it.
-
01
Anchor on long-horizon population data
UN, WHO, IHME GBD.
-
02
Layer NCD acceleration
CV, cancer, diabetes, CKD, dementia.
-
03
Track disruptive curves
AMR, climate-linked disease, mental health.
-
04
Model interaction effects
Comorbidity overlap inflates apparent prevalence — adjust.
-
05
Translate into TA-level forecast
Push every trend into the relevant TA model.
What separates a good answer from a defensible one.
Use ranges, not single-point forecasts.
Aging skews — Japan, Italy, Korea fastest.
Diagnosis improvement can outpace prevalence — both matter.
Vaccination, lifestyle policy and screening change curves.
Where the signal comes from.
Common questions.
How far out is realistic to forecast?
10 years with confidence; 20 years with explicit uncertainty bands. Beyond that, scenario rather than forecast.
Which trends move fastest?
AMR and climate-linked vector disease — slower than aging, but trajectory is steeper relative to baseline.
Want this answered on your data?
We build decision systems on top of analyses like this — so the next question takes minutes, not weeks.
Talk to a strategist